Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kulkarni, Tejaswini
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial	Active, not recruiting	4	70	US	Nintedanib, OFEV, Placebo, Standard of Care	Rohit Aggarwal, MD, Boehringer Ingelheim	Myositis Associated Interstitial Lund Disease (MA-ILD)	07/25	12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis May 2024 - Aug 2024 : Topline data for IPF Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF	Recruiting	3	576	Canada, US	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	06/25	06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis	Recruiting	3	698	Canada, US, RoW	Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer	United Therapeutics	Progressive Pulmonary Fibrosis, Interstitial Lung Disease	11/27	11/27
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Recruiting	2	270	Europe, Canada, US, RoW	Buloxibutid, C21, Placebo	Vicore Pharma AB, Population Services International	Idiopathic Pulmonary Fibrosis (IPF)	02/27	03/27
NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF	Terminated	2	46	Europe, US, RoW	LTP001, Placebo, Standard of Care (SoC)	Novartis Pharmaceuticals	Idiopathic Pulmonary Fibrosis	08/24	09/24